Here's an options play on this small pharma name that just scored an FDA win.
Here's what the charts and indicators say.
These recently downgraded names are displaying both quantitative and technical deterioration.
New Covid infections appear to be surging in China due to the rise of the XBB sub-lineage of the Omicron variant.
Here's what traders need to know.
It looks as though the answer could be yes as the shares of the biopharmaceutical company have built a nice base.
Let's review three pharma companies based outside the U.S. that promise reasonable valuations and solid dividend yields.
On top of all the other best-selling drugs in the firm's stable, Mounjaro has game-changer type potential.
I've noticed that biotech has been one area of strength lately.
Buyers have been acting more aggressively than sellers.